TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced NPC;~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;~* Normal complete blood count;~* Normal hepatic function;~* Normal renal function (creatinine ≤ 1.5 times the upper limit of normal).~Exclusion Criteria:~* Previous radiotherapy;~* A history of any other type of malignancy;~* Pregnancy or lactation;~* Allergy to anti-EGFR monoclonal antibody;~* Obvious disfunction of liver, renal, cardiac or lung function;~* Un controlled infection;~* Systemic metastasis or distant metastasis;~* Patients with severe gastrointestinal diseases;~* Patients with mental disorders affecting patient participation in trial judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Anti-EGFR arm (Type: EXPERIMENTAL): In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Insulin naïve subjects with type 2 diabetes treated with oral hypoglycemic agents~* Body mass index between 26 and 40 kg/m2~* HbA1c between 7.5% and 10.0%~* Fasting plasma glucose \>7.8 mmol/L and fasting C-peptide \> or =0.25 nmol/L

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fingolimod Effect on Cytokine and Chemokine Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Written informed consent must be obtained before the beginning of te study~2. Nonresponder RRMS patients~3. Last relapse of the patient should be at least 2 months before study entry.~4. Last interferon or glatiramer acetate dose of the patient should be at least 1 month before study entry.~Key Exclusion Criteria:~1. Patients with secondary progressive MS.~2. Patients with known contraindications for fingolimod treatment.~3. Other coexistent autoimmune diseases~4. Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- FTY720 (Type: EXPERIMENTAL): None
- Healthy volunteers (Type: NO_INTERVENTION): Healthy volunteers with no intervention or drug administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Treatment naive PCOS women having age from 14-45 years with scanty or no menstruation, hirsutism and elevated serum androgen levels, will be diagnosed on the basis of AES (Androgen access society) guidelines 2006 according to which when two of the following criteria are present patient will be said to have the syndrome~2. Hirsutism or hyperandrogenism~3. Oligo or an-ovulation and or polycystic ovaries~Exclusion Criteria:~1. Women with previous history of Cushing syndrome~2. Thyroid disorders~3. Hyperprolactinemia~4. Ovarian tumors~5. Congenital adrenal hyperplasia androgen-producing tumors,~6. History of seizures~7. Patients on warfarin, Coumadin and Sintrom because of drug interaction with acetyl-L-Carnitine,~8. Pregnancy or using contraceptive medications,~9. Patients on hormonal therapy that alters the biochemical or hormonal profile

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Combination Therapy Group (Type: ACTIVE_COMPARATOR): ARM 1: Resveratrol (1000mg Twice a day) Myoinositol (1000mg Twice a day)
- Standard Therapy Group (Type: OTHER): ARM 2:Metformin 500mg (Twice a day) Pioglitazone (15mg Twice a day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically documented squamous cell cancer of the head and neck in the following sites: Hypopharynx Larynx Oral cavity Oropharynx Stage III/IV disease No distant metastases by the following: Chest x-ray (all patients) Liver ultrasound or CT and bone scintigraphy (all hypopharyngeal cancers, those with involved lower neck nodes, and as clinically indicated) Multiple sites of disease eligible provided radiotherapy treatment volume remains acceptable~PATIENT CHARACTERISTICS: Age: 20 to 75 Performance status: WHO 0-2 Hematopoietic: WBC greater than 3,000 Platelets greater than 100,000 Hepatic: Not specified Renal: Creatinine clearance at least 60 ml/min No renal disease or impairment of renal function Cardiovascular: No coronary heart disease No cardiac failure No history of pulmonary embolism within 2 years Other: No clinical hearing impairment No peripheral neuropathy with concomitant handicap No severe diabetes mellitus with serious vasculopathy or neuropathy No second cancer except: Nonmelanomatous skin or lip cancer In situ carcinoma of the cervix Blood/body fluid analyses to determine eligibility completed within 14 days prior to registration~PRIOR CONCURRENT THERAPY: No prior treatment for head and neck cancer Excisional biopsy for diagnosis allowed

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * High-risk, localized disease that is previously untreated~ * Minimum of 2 positive biopsies~ * Meets at least 1 of the following criteria:~    * Stage T3~   * Serum PSA greater than 10 ng/mL~   * Gleason score 7-10~   * Gleason score 6 and at least 3 positive biopsies~* Potential candidate for radical prostatectomy~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10.0 g/dL~Hepatic~* Bilirubin normal~* AST and ALT normal~* PTT normal~* INR normal~Renal~* Creatinine normal~Cardiovascular~* No significant cardiac dysfunction~Other~* Fertile patients must use effective contraception~* No known hypersensitivity to oligonucleotides, luteinizing hormone-releasing hormone analogs, or anti-androgens~* No evidence of active uncontrolled infection~* No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer~* No other serious illness, psychiatric disorder, or medical condition that would preclude study compliance~* No history of a significant neurological disorder that would preclude informed consent~* No geographical condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for prostate cancer~Endocrine therapy~* No prior hormonal therapy for prostate cancer~Radiotherapy~* No prior radiotherapy for prostate cancer~* No concurrent radiotherapy~Surgery~* Not specified~Other~* No concurrent heparin or warfarin anticoagulation~* No other concurrent investigational therapy~* No other concurrent cytotoxic therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key inclusion Criteria:~* Diagnosis of Multiple Sclerosis (MS) as defined by revised McDonald criteria.~* A relapsing-remitting course of disease with at least 1 documented relapse during the previous year, or 2 documented relapses during the previous 2 years, or a positive gadolinium (Gd)-enhanced MRI scan at screening (in case the first MRI scan obtained at screening is negative, a second scan may be obtained 1 month later.)~* An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at randomization.~* Neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization.~* Patients who decline initiation or continuation of treatment with available disease modifying drugs for MS, for whatever reason, after having been informed about their respective benefits and possible adverse events by the investigator.~Key exclusion Criteria:~* A manifestation of another type of MS than RRMS~* History of chronic disease of the immune system other than MS~* Malignancies, diabetes, significant cardiovascular, pulmonary and hepatic diseases and conditions~* Active infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- BAF312 10mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 2 mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 0.5 mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 dose between 0.1 to 8 mg period 2 (Type: EXPERIMENTAL): None
- BAF312 dose between 0.1 - 8 mg period 2 (Type: EXPERIMENTAL): None
- Placebo (period 1, 2) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older.~* Diagnosis of focal epilepsy.~* Previous failure of one or more AEDs used in monotherapy.~* Background treatment with an antiepileptic drug.~* The investigator has considered that the patient must start treatment with some of the seven new AEDs in combination therapy: lamotrigine, levetiracetam, gabapentin, oxcarbazepine, pregabalin, tiagabine and/or topiramate.~* History of seizures in the patient in the past 3 months.~* The patient or legal guardian must be able to understand the characteristics of the study and fill in the seizure diaries.~* Written informed consent.~Exclusion Criteria:~* Inability to comply with the study requirements.~* Diagnosis of generalized epilepsy or inability to establish if focal or generalized.~* Presence of serious or uncontrolled systemic disease, serious psychiatric disease or progressive neurological disease.~* History of alcoholism, drug addiction, or abuse of medicines in the past two years.~* Psychogenic seizures in the two years prior to inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.0 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written Data Release Form (DRF) or informed consent using the Institutional Review Board (IRB)/ Ethic Committee (EC)-approved consent form and agrees to comply with protocol requirements.~* At least 18 years of age.~* Subject has already been selected for flow diversion therapy as the appropriate treatment.~* Subject has a target IA that has a parent vessel with diameter 1.5-5.0 mm distal/proximal to the target IA.~Exclusion Criteria:~* Major surgery including endovascular procedures within the past 30 days.~* Subject with target IA located in the basilar artery~* Subject with anatomy not appropriate for endovascular treatment due to severe intracranial vessel tortuosity or stenosis determined from baseline or pre-procedure imaging, or a history of intracranial vasospasm not responsive to medical therapy.~* Stent is in place in the parent artery at the target IA location.~* Subject with an acutely (within 30 days) ruptured aneurysm with a Hunt and Hess grade of 4 or higher.~* Any known contraindication to treatment with the Pipeline™ Flex Embolization Device with Shield Technology™ per Instructions for Use.~* The investigator determines that the health of the subject or the validity of the study outcomes (e.g., high risk of neurologic events, conditions that may increase the chance of stroke, worsening of clinical condition in the last 30 days) may be compromised by the subject's enrollment.~* Pregnant or breast-feeding women or women who wish to become pregnant during the length of study participation.~* Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from Medtronic.~* Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic heart failure (\>6 months duration)~* Stabilized on recommended or maximally tolerated dose of ACE-I/ARB or ARNI (unless contraindicated) and beta-blocker (unless contraindicated). If indicated, an aldosterone receptor antagonist should be given (unless contraindicated).~* Reduced ejection fraction defined as LVEF \< 45%~* NYHA-class II or III or IV with stable symptoms for at least the past 3 months~* Creatinine clearance \> 45 ml/min~Exclusion Criteria:~* Diabetes mellitus: Diabetes will be diagnosed using the 2018 The American Diabetes Association (ADA) Standards of Medical Care in Diabetes 15~  * FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.\*~ * 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.~ * A1C ≥6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.\*~ * In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).~* Any oral or injectable hypoglycemic therapy (e.g. insulin, sulfonylureas)~* Recent Hospitalizations in the past 3 months~* Metformin treatment within the last 3 months~* Creatinine clearance below 45 in the prior 6 months as assessed by Cockcroft and Gault equation~* Known allergy to metformin or major side effects to metformin treatment~* Atrial fibrillation with poorly controlled ventricular rate at rest (\> 100 beats/min)~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
- Standard of Care (Type: NO_INTERVENTION): Patients in the control arm will continue the SOC medications

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Actinic Keratosis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of at least 50 years~* Presence of four to fifteen clinically typical, visible, and discrete actinic keratoses in 25 cm2 on any of the four anatomical sites: scalp, face, right upper extremity and left upper extremity~* Ability and willingness of the patient to participate in the study (Informed consent is obtained)~Exclusion Criteria:~* Treatment area is within 5 cm of an incompletely healed wound or a suspected basal-cell or squamous-cell carcinoma~* Treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or lesions that had not responded to repeated cryotherapy~* Recent (within a month) use of medications that could interfere with evaluation of the treatment area (e.g., topical medications, artificial tanners, immunosuppressive medications, immunomodulating agents, cytotoxic drugs, ultraviolet B phototherapy, other therapies for actinic keratoses, or oral retinoids)~* Premenopausal Women (to avoid any risk of pregnancy)~* History of hypercalcemia or clinical evidence of vitamin D toxicity

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- calcipotriol plus 5-fluorouracil (Type: EXPERIMENTAL): calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
- 5-fluorouracil plus vaseline (Type: ACTIVE_COMPARATOR): 5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient must be at least 21 days after stem cell infusion~* Clinical status must allow tapering of steroids to \< 0.5mg/kg prednisone or other steroid equivalent~Exclusion Criteria:~* Patients who have developed viral infection or reactivation will be ineligible for prophylactic infusions of VSTs~* Active acute GVHD grades II-IV~* Uncontrolled relapse of malignancy~* Infusion of ATG or alemtuzumab within 2 weeks of VST infusion. Additionally, in patients who received alemtuzumab as part of their conditioning regimen, alemtuzumab levels will be collected in the second week following stem cell infusion. The level must be less than, or equal to, 0.15 prior to infusion of VSTs. In patients with level greater than 0.15, alemtuzumab levels can be checked serially until a level ≤ 0.15 is obtained. They would become eligible for prophylactic VST infusion at that point if there is still no evidence of viral infection at that time.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Viral Specific T-cells (VSTs) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete